# Divis Laboratories Ltd (DIVISLAB)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹6756.5
Day Change: -1.89%
52W High: ₹7077.7
52W Low: ₹5637.5
Market Cap: ₹1,79,486 Cr

## Valuation
P/E: 72.47
P/B: 11.64
EPS: ₹93.3
Book Value: ₹580.95
Dividend Yield: 0%

## Returns
1Y Return: 5.77%

## Profitability
ROE: 0%
ROCE: 19.71%
Debt/Equity: 0.01
Revenue Growth: 12.3%
Profit Growth: -1%
EBITDA Margin: 32.61%
Operating Margin: 29.65%

## About
Divi's Labs is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Pharma — Formulations

## Business Model
Overview: Divis Laboratories Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Core Business
- Other Segments
- Exports
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Business Segments:
- Core Business: 66% of tracked revenue, equal to ₹36,381 Cr. | 66% | ₹36,381 Cr
- Other Segments: 32% of tracked revenue, equal to ₹17,639 Cr. | 32% | ₹17,639 Cr
- Exports: 2% of tracked revenue, equal to ₹1,102 Cr. | 2% | ₹1,102 Cr
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Quarterly Report: Outcome Of Board Meeting Held On May 23, 2026
- BSE Filing: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-25T14:00:11.436Z
Price History Updated: 2026-05-25T05:26:28.308Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:26:28.308Z
Quant Updated: 2026-05-25T05:26:28.308Z
Sentiment Updated: 2026-05-25T05:26:28.308Z
Financials Status: current
Financials Updated: 2026-05-18T02:33:10.737Z
Financials Last Attempt: 2026-05-18T02:33:10.737Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹2532 Cr
Operating Profit: ₹1018 Cr (OPM 40%)
Net Profit: ₹773 Cr
Tax: ₹991 Cr

## Annual P&L History
Mar 2015: Rev ₹2532Cr | PAT ₹773Cr | OPM 40%
Mar 2016: Rev ₹3115Cr | PAT ₹852Cr | OPM 38%
Mar 2017: Rev ₹3776Cr | PAT ₹1126Cr | OPM 38%

## Balance Sheet (Mar 2015)
Total Assets: ₹3710 Cr
Total Liabilities: ₹3710 Cr
Borrowings: ₹18 Cr
Cash: ₹undefined Cr

## Shareholding
Promoters: 47.53%
FIIs: 19.65%
DIIs: 10.05%
Public: 22.77%

## Board
- Kiran Satchandra Divi B. Pharm., M.Pharm, CEO & Whole-Time Director
- Venkata Ramana Nimmagadda B.Sc.(Chem), Executive Director
- Murali Krishna Prasad Divi M. Pharm, Ph.D., MD & Executive Director
- Devendra Rao Sureddy M.Sc., Whole-Time Director (Manufacturing)
- Nilima Prasad Divi, Whole-time Director, Chief Control Officer & Director of Commercial

## Highlights
- Strong revenue growth of 16% CAGR over 5 years
- ROE of 15.0% indicates efficient capital allocation

## Concerns
- Debt-to-equity ratio needs monitoring amid expansion plans
- Promoter holding has seen slight decline in recent quarters

---
Source: rupiya.io/stocks/divislab
Disclaimer: For research and education only. Not investment advice.